Reducing cardiovascular mortality in chronic kidney disease

Something borrowed, something new

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Clinical vignette: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?

Original languageEnglish (US)
Pages (from-to)542-543
Number of pages2
JournalJournal of Clinical Investigation
Volume123
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Chlorthalidone
Vascular Calcification
Heart Sounds
Amlodipine
Cholecalciferol
Erythropoietin
Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
Hypertrophy
Heart Ventricles
Renal Dialysis
Foot
Edema
Electrocardiography
Thorax
Phosphates
X-Rays
Blood Pressure
Hypertension
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Reducing cardiovascular mortality in chronic kidney disease : Something borrowed, something new. / Quarles, Leigh.

In: Journal of Clinical Investigation, Vol. 123, No. 2, 01.02.2013, p. 542-543.

Research output: Contribution to journalArticle

@article{02bcafc2420d440ba5170418ad849cfe,
title = "Reducing cardiovascular mortality in chronic kidney disease: Something borrowed, something new",
abstract = "Clinical vignette: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?",
author = "Leigh Quarles",
year = "2013",
month = "2",
day = "1",
doi = "10.1172/JCI67203",
language = "English (US)",
volume = "123",
pages = "542--543",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Reducing cardiovascular mortality in chronic kidney disease

T2 - Something borrowed, something new

AU - Quarles, Leigh

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Clinical vignette: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?

AB - Clinical vignette: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?

UR - http://www.scopus.com/inward/record.url?scp=84873358213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873358213&partnerID=8YFLogxK

U2 - 10.1172/JCI67203

DO - 10.1172/JCI67203

M3 - Article

VL - 123

SP - 542

EP - 543

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -